These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31515132)

  • 1. Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.
    Melo M; Porter E; Zhang Y; Silva M; Li N; Dobosh B; Liguori A; Skog P; Landais E; Menis S; Sok D; Nemazee D; Schief WR; Weiss R; Irvine DJ
    Mol Ther; 2019 Dec; 27(12):2080-2090. PubMed ID: 31515132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.
    Duan H; Chen X; Boyington JC; Cheng C; Zhang Y; Jafari AJ; Stephens T; Tsybovsky Y; Kalyuzhniy O; Zhao P; Menis S; Nason MC; Normandin E; Mukhamedova M; DeKosky BJ; Wells L; Schief WR; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2018 Aug; 49(2):301-311.e5. PubMed ID: 30076101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
    Mu Z; Whitley J; Martik D; Sutherland L; Newman A; Barr M; Parks R; Wiehe K; Cain DW; Hodges KZ; Venkatayogi S; Lee EM; Smith L; Mansouri K; Edwards RJ; Wang Y; Rountree W; Alameh M-G; Tam Y; Barbosa C; Tomai M; Lewis MG; Santrai S; Maughan M; Tian M; Alt FW; Weissman D; Saunders KO; Haynes BF
    J Virol; 2024 Sep; 98(9):e0013724. PubMed ID: 39136461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
    Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.
    McGuire AT; Gray MD; Dosenovic P; Gitlin AD; Freund NT; Petersen J; Correnti C; Johnsen W; Kegel R; Stuart AB; Glenn J; Seaman MS; Schief WR; Strong RK; Nussenzweig MC; Stamatatos L
    Nat Commun; 2016 Feb; 7():10618. PubMed ID: 26907590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.
    Huang D; Abbott RK; Havenar-Daughton C; Skog PD; Al-Kolla R; Groschel B; Blane TR; Menis S; Tran JT; Thinnes TC; Volpi SA; Liguori A; Schiffner T; Villegas SM; Kalyuzhniy O; Pintea M; Voss JE; Phelps N; Tingle R; Rodriguez AR; Martin G; Kupryianov S; deCamp A; Schief WR; Nemazee D; Crotty S
    Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22920-22931. PubMed ID: 32873644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
    Antanasijevic A; Ueda G; Brouwer PJM; Copps J; Huang D; Allen JD; Cottrell CA; Yasmeen A; Sewall LM; Bontjer I; Ketas TJ; Turner HL; Berndsen ZT; Montefiori DC; Klasse PJ; Crispin M; Nemazee D; Moore JP; Sanders RW; King NP; Baker D; Ward AB
    PLoS Pathog; 2020 Aug; 16(8):e1008665. PubMed ID: 32780770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
    Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
    Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.
    Sok D; Briney B; Jardine JG; Kulp DW; Menis S; Pauthner M; Wood A; Lee EC; Le KM; Jones M; Ramos A; Kalyuzhniy O; Adachi Y; Kubitz M; MacPherson S; Bradley A; Friedrich GA; Schief WR; Burton DR
    Science; 2016 Sep; 353(6307):1557-1560. PubMed ID: 27608668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models.
    Wang X; Cottrell CA; Hu X; Ray R; Bottermann M; Villavicencio PM; Yan Y; Xie Z; Warner JE; Ellis-Pugh JR; Kalyuzhniy O; Liguori A; Willis JR; Menis S; Rämisch S; Eskandarzadeh S; Kubitz M; Tingle R; Phelps N; Groschel B; Himansu S; Carfi A; Kirsch KH; Weldon SR; Nair U; Schief WR; Batista FD
    Sci Immunol; 2024 May; 9(95):eadn0622. PubMed ID: 38753808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.
    Parks KR; MacCamy AJ; Trichka J; Gray M; Weidle C; Borst AJ; Khechaduri A; Takushi B; Agrawal P; Guenaga J; Wyatt RT; Coler R; Seaman M; LaBranche C; Montefiori DC; Veesler D; Pancera M; McGuire A; Stamatatos L
    Cell Rep; 2019 Dec; 29(10):3060-3072.e7. PubMed ID: 31801073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.
    Xie Z; Lin YC; Steichen JM; Ozorowski G; Kratochvil S; Ray R; Torres JL; Liguori A; Kalyuzhniy O; Wang X; Warner JE; Weldon SR; Dale GA; Kirsch KH; Nair U; Baboo S; Georgeson E; Adachi Y; Kubitz M; Jackson AM; Richey ST; Volk RM; Lee JH; Diedrich JK; Prum T; Falcone S; Himansu S; Carfi A; Yates JR; Paulson JC; Sok D; Ward AB; Schief WR; Batista FD
    Science; 2024 May; 384(6697):eadk0582. PubMed ID: 38753770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms.
    Brouwer PJM; Sanders RW
    Curr Opin HIV AIDS; 2019 Jul; 14(4):302-308. PubMed ID: 30994503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
    McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
    J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
    Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
    Front Immunol; 2019; 10():2941. PubMed ID: 31921191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
    Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers.
    Lee JH; Hu JK; Georgeson E; Nakao C; Groschel B; Dileepan T; Jenkins MK; Seumois G; Vijayanand P; Schief WR; Crotty S
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33355623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.